Panobinosta (Farydak)
Targeted Therapy · Approved since 2015
Description
Panobinostat is a pan-histone deacetylase (HDAC) inhibitor that has been evaluated in colorectal cancer treatment, particularly in combination with fluorouracil-based regimens for metastatic disease. This epigenetic modifier works by altering gene expression patterns in cancer cells and has been studied in patients with stage IV colorectal cancer who have not responded to previous fluoropyrimidine therapy. Panobinostat represents part of combination approaches that include immunotherapy agents like PDR001 and other targeted therapies for advanced colorectal cancer.
Mechanism of Action
Panobinostat inhibits multiple classes of histone deacetylases (HDACs), enzymes that remove acetyl groups from histone proteins and regulate gene transcription. By blocking HDAC activity, panobinostat increases histone acetylation, leading to chromatin relaxation and reactivation of tumor suppressor genes that are silenced in cancer cells. This epigenetic modification can restore normal cell cycle control and promote cancer cell death.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Farydak |
| Category | Targeted Therapy |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 2015 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.